Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Gilbert

Showing results (81-90 of 91) with videos related to

Pageof 10
Sort By:
The New England Journal of Medicine|December 30, 2020
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 VaccineLindsey R Baden, Hana M El Sahly, Brandon Essink, et al.
The Journal of Infectious Diseases|May 29, 2012
Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trialsDavid C Montefiori, Chitraporn Karnasuta, Ying Huang, et al.
Water Research|July 21, 2018
The interplay between total mercury, methylmercury and dissolved organic matter in fluvial systems: A latitudinal study across EuropeAndrea G Bravo, Dolly N Kothawala, Katrin Attermeyer, et al.
Plos Pathogens|December 8, 2020
RV144 HIV-1 vaccination impacts post-infection antibody responsesThembi Mdluli, Ningbo Jian, Bonnie Slike, et al.
Plos Pathogens|March 2, 2021
Correction: RV144 HIV-1 vaccination impacts post-infection antibody responsesThembi Mdluli, Ningbo Jian, Bonnie Slike, et al.
AIDS Research and Human Retroviruses|October 6, 2012
The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120Nicos Karasavvas, Erik Billings, Mangala Rao, et al.
The New England Journal of Medicine|September 22, 2021
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded PhaseHana M El Sahly, Lindsey R Baden, Brandon Essink, et al.
Research Square|July 3, 2023
Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence featuresCraig Magaret, Li Li, Allan deCamp, et al.
The Journal of Clinical Investigation|June 9, 2015
Maternal HIV-1 envelope-specific antibody responses and reduced risk of perinatal transmissionSallie R Permar, Youyi Fong, Nathan Vandergrift, et al.
Science (New York, N.Y.)|August 1, 2015
HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodiesWilton B Williams, Hua-Xin Liao, M Anthony Moody, et al.
Pageof 10

Showing results (81-90 of 91) with videos related to

Sort By:
Pageof 10
The New England Journal of Medicine|December 30, 2020
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 VaccineLindsey R Baden, Hana M El Sahly, Brandon Essink, et al.
The Journal of Infectious Diseases|May 29, 2012
Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trialsDavid C Montefiori, Chitraporn Karnasuta, Ying Huang, et al.
Water Research|July 21, 2018
The interplay between total mercury, methylmercury and dissolved organic matter in fluvial systems: A latitudinal study across EuropeAndrea G Bravo, Dolly N Kothawala, Katrin Attermeyer, et al.
Plos Pathogens|December 8, 2020
RV144 HIV-1 vaccination impacts post-infection antibody responsesThembi Mdluli, Ningbo Jian, Bonnie Slike, et al.
Plos Pathogens|March 2, 2021
Correction: RV144 HIV-1 vaccination impacts post-infection antibody responsesThembi Mdluli, Ningbo Jian, Bonnie Slike, et al.
AIDS Research and Human Retroviruses|October 6, 2012
The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120Nicos Karasavvas, Erik Billings, Mangala Rao, et al.
The New England Journal of Medicine|September 22, 2021
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded PhaseHana M El Sahly, Lindsey R Baden, Brandon Essink, et al.
Research Square|July 3, 2023
Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence featuresCraig Magaret, Li Li, Allan deCamp, et al.
The Journal of Clinical Investigation|June 9, 2015
Maternal HIV-1 envelope-specific antibody responses and reduced risk of perinatal transmissionSallie R Permar, Youyi Fong, Nathan Vandergrift, et al.
Science (New York, N.Y.)|August 1, 2015
HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodiesWilton B Williams, Hua-Xin Liao, M Anthony Moody, et al.
Pageof 10